期刊
INFECTION
卷 43, 期 2, 页码 145-151出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s15010-015-0749-y
关键词
Tedizolid; Ceftolozane; Omadacycline; Avibactam; Cadazolid
资金
- Deutsches Zentrum fur Infektionsforschung (DZIF), Munich
Therapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gram-negative organisms, new antibiotics are urgently needed. This paper provides a review of novel antibiotic compounds which are already in clinical development, mainly in phase III clinical trials. Each of these new trials increases the possibility of new antibiotics receiving approval.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据